Does the media prefer BBIO or RLAY?

In the previous week, BridgeBio Pharma had 12 more articles in the media than Relay Therapeutics. MarketBeat recorded 23 mentions for BridgeBio Pharma and 11 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.83 beat BridgeBio Pharma's score of 0.61 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 3 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASND or RLAY?

In the previous week, Ascendis Pharma A/S had 1 more articles in the media than Relay Therapeutics. MarketBeat recorded 12 mentions for Ascendis Pharma A/S and 11 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.83 beat Ascendis Pharma A/S's score of 0.17 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relay Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, RLAY or EXEL?

Exelixis has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relay Therapeutics $15.35M 294.23 -$276.48M -$1.57 N/A Exelixis $2.32B 5.67 $782.57M $3.18 16.70

Does the media favor RLAY or EXEL?

In the previous week, Exelixis had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 13 mentions for Exelixis and 11 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.83 beat Exelixis' score of 0.73 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RLAY or BMRN?

In the previous week, BioMarin Pharmaceutical had 11 more articles in the media than Relay Therapeutics. MarketBeat recorded 22 mentions for BioMarin Pharmaceutical and 11 mentions for Relay Therapeutics. BioMarin Pharmaceutical's average media sentiment score of 1.04 beat Relay Therapeutics' score of 0.83 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 9 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARWR or RLAY?

In the previous week, Relay Therapeutics had 6 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 11 mentions for Relay Therapeutics and 5 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.19 beat Relay Therapeutics' score of 0.83 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Relay Therapeutics (RLAY) Competitors

$20.61 -0.06 (-0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$20.66 +0.05 (+0.22%)

As of 07:56 PM Eastern

Compare

RLAY vs. BBIO, ASND, EXEL, BMRN, and ARWR

Should you buy Relay Therapeutics stock or one of its competitors? Relay Therapeutics's main competitors and comparable companies include BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), and Arrowhead Pharmaceuticals (ARWR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Relay Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

BridgeBio Pharma has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market.

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, BridgeBio Pharma had 12 more articles in the media than Relay Therapeutics. MarketBeat recorded 23 mentions for BridgeBio Pharma and 11 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.83 beat BridgeBio Pharma's score of 0.61 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	3 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma currently has a consensus price target of $100.79, suggesting a potential upside of 21.46%. Relay Therapeutics has a consensus price target of $25.83, suggesting a potential upside of 25.34%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Relay Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86

Relay Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Relay Therapeutics	N/A	-42.27%	-38.67%

Relay Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	32.31	-$724.93M	-$3.57	N/A
Relay Therapeutics	$15.35M	294.23	-$276.48M	-$1.57	N/A

Summary

Relay Therapeutics beats BridgeBio Pharma on 11 of the 17 factors compared between the two stocks.

How does Relay Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Ascendis Pharma A/S has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

Ascendis Pharma A/S has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.06	-$258M	$12.89	19.31
Relay Therapeutics	$15.35M	294.23	-$276.48M	-$1.57	N/A

Ascendis Pharma A/S currently has a consensus price target of $300.33, suggesting a potential upside of 20.69%. Relay Therapeutics has a consensus price target of $25.83, suggesting a potential upside of 25.34%. Given Relay Therapeutics' higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86

In the previous week, Ascendis Pharma A/S had 1 more articles in the media than Relay Therapeutics. MarketBeat recorded 12 mentions for Ascendis Pharma A/S and 11 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.83 beat Ascendis Pharma A/S's score of 0.17 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relay Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Relay Therapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ascendis Pharma A/S has a net margin of 70.99% compared to Relay Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Relay Therapeutics	N/A	-42.27%	-38.67%

Summary

Ascendis Pharma A/S beats Relay Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Relay Therapeutics compare to Exelixis?

Relay Therapeutics (NASDAQ:RLAY) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Relay Therapeutics presently has a consensus price target of $25.83, suggesting a potential upside of 25.34%. Exelixis has a consensus price target of $50.07, suggesting a potential downside of 5.75%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Relay Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30

Relay Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Exelixis has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	294.23	-$276.48M	-$1.57	N/A
Exelixis	$2.32B	5.67	$782.57M	$3.18	16.70

In the previous week, Exelixis had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 13 mentions for Exelixis and 11 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.83 beat Exelixis' score of 0.73 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a net margin of 35.33% compared to Relay Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Exelixis	35.33%	42.17%	31.76%

Summary

Relay Therapeutics beats Exelixis on 9 of the 17 factors compared between the two stocks.

How does Relay Therapeutics compare to BioMarin Pharmaceutical?

Relay Therapeutics (NASDAQ:RLAY) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Relay Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

BioMarin Pharmaceutical has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	294.23	-$276.48M	-$1.57	N/A
BioMarin Pharmaceutical	$3.22B	4.03	$348.90M	$0.37	181.05

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, BioMarin Pharmaceutical had 11 more articles in the media than Relay Therapeutics. MarketBeat recorded 22 mentions for BioMarin Pharmaceutical and 11 mentions for Relay Therapeutics. BioMarin Pharmaceutical's average media sentiment score of 1.04 beat Relay Therapeutics' score of 0.83 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	9 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics presently has a consensus price target of $25.83, suggesting a potential upside of 25.34%. BioMarin Pharmaceutical has a consensus price target of $88.41, suggesting a potential upside of 31.97%. Given BioMarin Pharmaceutical's higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.70

BioMarin Pharmaceutical has a net margin of 2.14% compared to Relay Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Summary

BioMarin Pharmaceutical beats Relay Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Relay Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

In the previous week, Relay Therapeutics had 6 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 11 mentions for Relay Therapeutics and 5 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.19 beat Relay Therapeutics' score of 0.83 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Relay Therapeutics' return on equity of -42.27% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Relay Therapeutics	N/A	-42.27%	-38.67%

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Arrowhead Pharmaceuticals has higher revenue and earnings than Relay Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.93	-$1.63M	-$2.25	N/A
Relay Therapeutics	$15.35M	294.23	-$276.48M	-$1.57	N/A

Arrowhead Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market.

Arrowhead Pharmaceuticals currently has a consensus target price of $97.33, suggesting a potential upside of 10.73%. Relay Therapeutics has a consensus target price of $25.83, suggesting a potential upside of 25.34%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Relay Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86

Summary

Relay Therapeutics beats Arrowhead Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

Get Relay Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLAY vs. The Competition

Export

Metric	Relay Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.35B	$3.74B	$7.06B	$13.07B
Dividend Yield	N/A	3.69%	2.56%	10.63%
P/E Ratio	-13.13	6.79	211.15	21.15
Price / Sales	294.23	1,298.66	609.60	93.12
Price / Cash	N/A	44.90	28.88	38.50
Price / Book	6.30	17.82	11.33	6.43
Net Income	-$276.48M	-$12.50M	$3.46B	$348.18M
7 Day Performance	3.10%	1.26%	1.13%	0.16%
1 Month Performance	3.52%	3.15%	2.62%	1.48%
1 Year Performance	493.95%	55.49%	62.66%	19.34%

Relay Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLAY Relay Therapeutics	3.28 of 5 stars	$20.61 -0.3%	$25.83 +25.3%	+483.9%	$4.35B	$15.35M	N/A	330	News Coverage Analyst Downgrade
BBIO BridgeBio Pharma	3.2522 of 5 stars	$84.67 +0.2%	$97.33 +15.0%	+55.7%	$16.51B	$502.08M	N/A	400
ASND Ascendis Pharma A/S	4.3978 of 5 stars	$255.62 +0.1%	$296.12 +15.8%	+24.7%	$15.93B	$814.57M	29.48	1,189	Earnings Report Analyst Upgrade
EXEL Exelixis	2.8639 of 5 stars	$52.96 -2.1%	$49.79 -6.0%	+36.6%	$13.59B	$2.32B	16.65	1,077	Analyst Forecast
BMRN BioMarin Pharmaceutical	4.8483 of 5 stars	$68.88 +7.9%	$88.00 +27.8%	+15.8%	$12.35B	$3.22B	186.16	3,221	Trending News Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLAY) was last updated on 8/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relay Therapeutics (RLAY) Competitors

RLAY vs. BBIO, ASND, EXEL, BMRN, and ARWR

How does Relay Therapeutics compare to BridgeBio Pharma?

Summary

How does Relay Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Relay Therapeutics compare to Exelixis?

Summary

How does Relay Therapeutics compare to BioMarin Pharmaceutical?

Summary

How does Relay Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY vs. The Competition

Relay Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Relay Therapeutics (RLAY) Competitors

RLAY vs. BBIO, ASND, EXEL, BMRN, and ARWR

How does Relay Therapeutics compare to BridgeBio Pharma?

Which has more volatility & risk, BBIO or RLAY?

Do institutionals & insiders hold more shares of BBIO or RLAY?

Does the media prefer BBIO or RLAY?

Do analysts rate BBIO or RLAY?

Is BBIO or RLAY more profitable?

Which has better earnings & valuation, BBIO or RLAY?

Summary

How does Relay Therapeutics compare to Ascendis Pharma A/S?

Which has more risk & volatility, ASND or RLAY?

Which has preferable valuation and earnings, ASND or RLAY?

Do analysts rate ASND or RLAY?

Does the media prefer ASND or RLAY?

Do insiders and institutionals hold more shares of ASND or RLAY?

Is ASND or RLAY more profitable?

Summary

How does Relay Therapeutics compare to Exelixis?

Do insiders and institutionals have more ownership in RLAY or EXEL?

Do analysts prefer RLAY or EXEL?

Which has more volatility & risk, RLAY or EXEL?

Which has preferable earnings and valuation, RLAY or EXEL?

Does the media favor RLAY or EXEL?

Is RLAY or EXEL more profitable?

Summary

How does Relay Therapeutics compare to BioMarin Pharmaceutical?

Which has more volatility & risk, RLAY or BMRN?

Which has stronger valuation and earnings, RLAY or BMRN?

Do institutionals and insiders hold more shares of RLAY or BMRN?

Does the media favor RLAY or BMRN?

Do analysts recommend RLAY or BMRN?

Is RLAY or BMRN more profitable?

Summary

How does Relay Therapeutics compare to Arrowhead Pharmaceuticals?

Does the media prefer ARWR or RLAY?

Is ARWR or RLAY more profitable?

Do insiders & institutionals have more ownership in ARWR or RLAY?

Which has stronger valuation & earnings, ARWR or RLAY?

Which has more risk & volatility, ARWR or RLAY?

Do analysts recommend ARWR or RLAY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY vs. The Competition

Relay Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools